DE2332602A1 - Pentanolderivate, verfahren zu deren herstellung und diese enthaltende therapeutische praeparate - Google Patents
Pentanolderivate, verfahren zu deren herstellung und diese enthaltende therapeutische praeparateInfo
- Publication number
- DE2332602A1 DE2332602A1 DE2332602A DE2332602A DE2332602A1 DE 2332602 A1 DE2332602 A1 DE 2332602A1 DE 2332602 A DE2332602 A DE 2332602A DE 2332602 A DE2332602 A DE 2332602A DE 2332602 A1 DE2332602 A1 DE 2332602A1
- Authority
- DE
- Germany
- Prior art keywords
- group
- dose
- propyl
- animals
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 13
- 230000001225 therapeutic effect Effects 0.000 title claims description 9
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical class CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 title claims description 8
- 230000008569 process Effects 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 91
- 241001465754 Metazoa Species 0.000 description 52
- 238000012360 testing method Methods 0.000 description 33
- 239000000935 antidepressant agent Substances 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 21
- 229940005513 antidepressants Drugs 0.000 description 17
- 230000001430 anti-depressive effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 229960004801 imipramine Drugs 0.000 description 12
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 12
- 229940126062 Compound A Drugs 0.000 description 11
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 11
- 230000001914 calming effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000001624 sedative effect Effects 0.000 description 11
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 10
- 229960003529 diazepam Drugs 0.000 description 10
- 239000000932 sedative agent Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000000949 anxiolytic effect Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002249 anxiolytic agent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000000744 eyelid Anatomy 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000011514 reflex Effects 0.000 description 5
- JSUAJTLKVREZHV-UHFFFAOYSA-N 1-[4-(1-pyrrolidinyl)but-2-ynyl]pyrrolidine Chemical compound C1CCCN1CC#CCN1CCCC1 JSUAJTLKVREZHV-UHFFFAOYSA-N 0.000 description 4
- ASRCWEXFOAWADB-UHFFFAOYSA-N 4-propylheptan-3-one Chemical compound CCCC(CCC)C(=O)CC ASRCWEXFOAWADB-UHFFFAOYSA-N 0.000 description 4
- 206010015995 Eyelid ptosis Diseases 0.000 description 4
- -1 alkyl cadmium chloride Chemical compound 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 206010007776 catatonia Diseases 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- 231100000189 neurotoxic Toxicity 0.000 description 4
- 230000002887 neurotoxic effect Effects 0.000 description 4
- 201000003004 ptosis Diseases 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- YCBOPMITSGZJDX-UHFFFAOYSA-N 2-propylpentanenitrile Chemical compound CCCC(C#N)CCC YCBOPMITSGZJDX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940025084 amphetamine Drugs 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 231100001231 less toxic Toxicity 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229960005152 pentetrazol Drugs 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 229960002695 phenobarbital Drugs 0.000 description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 229940125723 sedative agent Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- PITHYUDHKJKJNQ-UHFFFAOYSA-N 2-propylpentanoyl chloride Chemical compound CCCC(C(Cl)=O)CCC PITHYUDHKJKJNQ-UHFFFAOYSA-N 0.000 description 2
- FQWBTHWBVNKOLD-UHFFFAOYSA-N 4-propylheptan-3-ol Chemical compound CCCC(CCC)C(O)CC FQWBTHWBVNKOLD-UHFFFAOYSA-N 0.000 description 2
- JEBLPNCAYFNVJX-UHFFFAOYSA-N 4-propylheptan-3-yl carbamate Chemical compound CCCC(CCC)C(CC)OC(N)=O JEBLPNCAYFNVJX-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 241000883306 Huso huso Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 230000002539 anti-aggressive effect Effects 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000002903 catalepsic effect Effects 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- QNVRIHYSUZMSGM-UHFFFAOYSA-N hexan-2-ol Chemical compound CCCCC(C)O QNVRIHYSUZMSGM-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000000506 psychotropic effect Effects 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- QNVRIHYSUZMSGM-LURJTMIESA-N 2-Hexanol Natural products CCCC[C@H](C)O QNVRIHYSUZMSGM-LURJTMIESA-N 0.000 description 1
- LASHFHLFDRTERB-UHFFFAOYSA-N 2-propylpentan-1-ol Chemical class CCCC(CO)CCC LASHFHLFDRTERB-UHFFFAOYSA-N 0.000 description 1
- RXFAGYKLLRXFDX-UHFFFAOYSA-N 3-propylhexan-2-one Chemical compound CCCC(C(C)=O)CCC RXFAGYKLLRXFDX-UHFFFAOYSA-N 0.000 description 1
- RQSKZAFRPIXLJU-UHFFFAOYSA-N 4-propylnonan-5-ol Chemical compound CCCCC(O)C(CCC)CCC RQSKZAFRPIXLJU-UHFFFAOYSA-N 0.000 description 1
- ZHGVZNPOYNUEOA-UHFFFAOYSA-N 4-propylnonan-5-one Chemical compound CCCCC(=O)C(CCC)CCC ZHGVZNPOYNUEOA-UHFFFAOYSA-N 0.000 description 1
- XUNDRCPTNXAFRK-UHFFFAOYSA-N 5-propyloctan-4-one Chemical compound CCCC(CCC)C(=O)CCC XUNDRCPTNXAFRK-UHFFFAOYSA-N 0.000 description 1
- 229910000838 Al alloy Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- YKYOUMDCQGMQQO-UHFFFAOYSA-L Cadmium chloride Inorganic materials Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- RZKSECIXORKHQS-UHFFFAOYSA-N Heptan-3-ol Chemical compound CCCCC(O)CC RZKSECIXORKHQS-UHFFFAOYSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241001230284 Theclini Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- DOXYUCZSYSEALW-UHFFFAOYSA-N dodecan-5-one Chemical compound CCCCCCCC(=O)CCCC DOXYUCZSYSEALW-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000001795 light effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N n-butyl methyl ketone Natural products CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- WOFPPJOZXUTRAU-UHFFFAOYSA-N octan-4-ol Chemical compound CCCCC(O)CCC WOFPPJOZXUTRAU-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036421 sense of balance Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
- C07C29/145—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones with hydrogen or hydrogen-containing gases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C31/02—Monohydroxylic acyclic alcohols
- C07C31/125—Monohydroxylic acyclic alcohols containing five to twenty-two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3060072A GB1384442A (en) | 1972-06-29 | 1972-06-29 | Pentanols and their carbamate derivatives and process for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2332602A1 true DE2332602A1 (de) | 1974-01-17 |
Family
ID=10310180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2332602A Pending DE2332602A1 (de) | 1972-06-29 | 1973-06-27 | Pentanolderivate, verfahren zu deren herstellung und diese enthaltende therapeutische praeparate |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPS4949907A (cs) |
| AR (2) | AR201005A1 (cs) |
| AT (1) | AT325015B (cs) |
| AU (1) | AU474132B2 (cs) |
| BE (1) | BE801323A (cs) |
| CA (1) | CA996946A (cs) |
| CH (1) | CH576952A5 (cs) |
| DE (1) | DE2332602A1 (cs) |
| ES (1) | ES416424A1 (cs) |
| FR (1) | FR2190445B1 (cs) |
| GB (1) | GB1384442A (cs) |
| HU (1) | HU168411B (cs) |
| IE (1) | IE37859B1 (cs) |
| NL (1) | NL7309079A (cs) |
| NO (1) | NO137496C (cs) |
| OA (1) | OA04535A (cs) |
| SE (1) | SE387626B (cs) |
| SU (2) | SU556720A3 (cs) |
| ZA (1) | ZA734074B (cs) |
-
1972
- 1972-06-29 GB GB3060072A patent/GB1384442A/en not_active Expired
-
1973
- 1973-06-15 ZA ZA734074A patent/ZA734074B/xx unknown
- 1973-06-19 FR FR7322179A patent/FR2190445B1/fr not_active Expired
- 1973-06-21 CH CH906073A patent/CH576952A5/xx not_active IP Right Cessation
- 1973-06-21 AU AU57183/73A patent/AU474132B2/en not_active Expired
- 1973-06-22 BE BE132618A patent/BE801323A/xx unknown
- 1973-06-25 OA OA54952A patent/OA04535A/xx unknown
- 1973-06-25 AR AR248720A patent/AR201005A1/es active
- 1973-06-27 DE DE2332602A patent/DE2332602A1/de active Pending
- 1973-06-27 HU HULA828A patent/HU168411B/hu unknown
- 1973-06-27 SU SU1930699A patent/SU556720A3/ru active
- 1973-06-27 AT AT565573A patent/AT325015B/de not_active IP Right Cessation
- 1973-06-28 SE SE7309129*A patent/SE387626B/xx unknown
- 1973-06-28 CA CA175,184A patent/CA996946A/en not_active Expired
- 1973-06-28 ES ES416424A patent/ES416424A1/es not_active Expired
- 1973-06-28 IE IE1084/73A patent/IE37859B1/xx unknown
- 1973-06-28 NO NO2691/73A patent/NO137496C/no unknown
- 1973-06-29 NL NL7309079A patent/NL7309079A/xx not_active Application Discontinuation
- 1973-06-29 JP JP48074322A patent/JPS4949907A/ja active Pending
- 1973-10-26 AR AR250720A patent/AR198331A1/es active
-
1974
- 1974-12-08 SU SU742080925A patent/SU625601A3/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| AR201005A1 (es) | 1975-02-06 |
| SE387626B (sv) | 1976-09-13 |
| BE801323A (fr) | 1973-12-26 |
| HU168411B (cs) | 1976-04-28 |
| NL7309079A (cs) | 1974-01-02 |
| ZA734074B (en) | 1974-07-31 |
| FR2190445B1 (cs) | 1977-09-09 |
| OA04535A (fr) | 1980-03-30 |
| AU5718373A (en) | 1975-01-09 |
| CA996946A (en) | 1976-09-14 |
| AT325015B (de) | 1975-09-25 |
| ES416424A1 (es) | 1976-03-01 |
| NO137496C (no) | 1978-03-08 |
| IE37859L (en) | 1973-12-29 |
| SU556720A3 (ru) | 1977-04-30 |
| AU474132B2 (en) | 1976-07-15 |
| SU625601A3 (ru) | 1978-09-25 |
| FR2190445A1 (cs) | 1974-02-01 |
| IE37859B1 (en) | 1977-10-26 |
| JPS4949907A (cs) | 1974-05-15 |
| AR198331A1 (es) | 1974-06-14 |
| NO137496B (no) | 1977-11-28 |
| GB1384442A (en) | 1975-02-19 |
| CH576952A5 (cs) | 1976-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3876877T2 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
| DE69231680T2 (de) | Neue verwendung von diphenylbutyl-piperazincarboxamiden zur behandlung von störungen im zusammenhang mit der verwendung giftiger stoffen | |
| DE3709621A1 (de) | Therapeutisches mittel | |
| DE69731968T2 (de) | Isovaleramid zur behandlung von schüttelkrämpfen, epilepsie, kopfschmerzen und spastischer lähmung | |
| EP0752246A2 (de) | Kappa-Opiate für entzündliche Darmerkrankungen | |
| DE2350222A1 (de) | Pharmazeutische mittel, die ein 4-aryl-2-(3-pyridyl)-thiazol enthalten, und ihre anwendung | |
| DD201797A5 (de) | Verfahren zur herstellung von dihydro-1h-pyrrolizin-3,5(2h,6h)-dion | |
| DE2351345A1 (de) | Therapeutische zubereitung | |
| DE2034640C3 (de) | l-p-(7-Trifluormethyl-4-chinolyl) -amino-benzoyl-piperazine, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Bluthochdruck | |
| DE2332602A1 (de) | Pentanolderivate, verfahren zu deren herstellung und diese enthaltende therapeutische praeparate | |
| DE2525064C2 (de) | Arzneimittel mit Antiparkinson-Wirkung | |
| DE2749520A1 (de) | Harnstoffderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische und veterinaermedizinische zusammensetzungen | |
| EP0471388A2 (de) | Mittel zur Behandlung der Herzinsuffizienz | |
| DE2755017C2 (cs) | ||
| DE60108650T2 (de) | 1-amino-alkylcyclohexanederivate als trypanocide mittel | |
| DE2542154C2 (de) | 6-(3-Chlor)phenoxy-3-methyl-2-oxo-1-aza-4-oxa-spiro[4,5]-decan, Verfahren zu seiner Herstellung und es enthaltende Arzneimittel | |
| DE3231571C2 (cs) | ||
| DE2648830B2 (de) | 2-Pyrrolidon-5-carbonsäuresalz des Kreatinin!, Verfahren zu dessen Herstellung und dieses enthaltendes pharmazeutisches Mittel | |
| DE2501649C3 (de) | Thiophen-2-carbonsäuresalz des Papaverins, Verfahren zu seiner Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| AT335469B (de) | Verfahren zur herstellung des neuen 4-(n-propyl)-n-heptanol-3-carbamates | |
| DE1617508C3 (de) | Antidepressive Mittel | |
| DE2227842C3 (de) | Diphenylcyclopentane und diese enthaltende Arzneimittel | |
| DE60216090T2 (de) | Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia | |
| DE10120159A1 (de) | NMDA-Antagonisten und NMDA-Agonisten zur Behandlung von Suchterkrankungen | |
| DE2336560A1 (de) | Arzneimittel, enthaltend (1-(2hydroxy-2-indanyl)-propylamin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHA | Expiration of time for request for examination |